"Placebos" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol.
| Descriptor ID |
D010919
|
| MeSH Number(s) |
D26.660 E02.785
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Placebos".
Below are MeSH descriptors whose meaning is more specific than "Placebos".
This graph shows the total number of publications written about "Placebos" by people in this website by year, and whether "Placebos" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 4 | 4 |
| 1995 | 0 | 3 | 3 |
| 1996 | 0 | 4 | 4 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 7 | 7 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 6 | 6 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 5 | 5 |
| 2003 | 1 | 3 | 4 |
| 2004 | 1 | 6 | 7 |
| 2005 | 1 | 7 | 8 |
| 2006 | 0 | 4 | 4 |
| 2007 | 0 | 8 | 8 |
| 2008 | 2 | 9 | 11 |
| 2009 | 0 | 6 | 6 |
| 2010 | 0 | 9 | 9 |
| 2011 | 0 | 10 | 10 |
| 2012 | 0 | 9 | 9 |
| 2013 | 0 | 4 | 4 |
| 2014 | 1 | 2 | 3 |
| 2015 | 0 | 4 | 4 |
| 2016 | 0 | 3 | 3 |
| 2017 | 0 | 5 | 5 |
| 2018 | 1 | 4 | 5 |
| 2019 | 0 | 5 | 5 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 6 | 6 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Placebos" by people in Profiles.
-
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure. Clin Gastroenterol Hepatol. 2024 Oct; 22(10):2096-2106.
-
PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. J Clin Endocrinol Metab. 2022 01 01; 107(1):e372-e385.
-
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol. 2022 01; 7(1):17-27.
-
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2022 03; 76(3):536-548.
-
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2022 03; 76(3):506-517.
-
Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism. J Clin Endocrinol Metab. 2021 10 21; 106(11):e4400-e4413.
-
Adjunctive Aspirin vs Placebo in Patients With Schizophrenia: Results of Two Randomized Controlled Trials. Schizophr Bull. 2021 07 08; 47(4):1077-1087.
-
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021 04; 22(4):450-462.
-
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. Am Heart J. 2021 03; 233:141-148.
-
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial. Clin J Am Soc Nephrol. 2020 12 31; 16(1):59-69.